Evidence map›Paper›PMID 38136582›Full record

ArticleBiomolecules2023

A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine Model.

Julia Mester-Tonczar, Patrick Einzinger, Ena Hasimbegovic, Nina Kastner, Victor Schweiger, Andreas Spannbauer, Emilie Han, Katrin Müller-Zlabinger, Denise Traxler-Weidenauer, Jutta Bergler-Klein and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Julia Mester-TonczarDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-1426-6670
Patrick EinzingerResearch Unit of Information and Software, Institute of Information Systems Engineering, 1040 Vienna, Austria.ORCID 0000-0002-2141-4953
Ena HasimbegovicDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
Nina KastnerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-1576-9029
Victor SchweigerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
Andreas SpannbauerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-9819-0361
Emilie HanDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-3064-1277
Katrin Müller-ZlabingerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-3855-7643
Denise Traxler-WeidenauerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-8679-1525
Jutta Bergler-KleinDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
Mariann GyöngyösiDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-7083-2107
Dominika LukovicDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-8040-8086
Medical University of Vienna · AT

Funding

TEVA Ratiopharm Teva Ratiopharm Industries
6 · The paper itself

Abstract

Despite the widespread use of doxorubicin (DOX) as a chemotherapeutic agent, its severe cumulative cardiotoxicity represents a significant limitation. While the liposomal encapsulation of doxorubicin (Myocet, MYO) reduces cardiotoxicity, it is crucial to understand the molecular background of doxorubicin-induced cardiotoxicity. Here, we examined circular RNA expression in a translational model of pigs treated with either DOX or MYO and its potential impact on the global gene expression pattern in the myocardium. This study furthers our knowledge about the regulatory network of circRNA/miRNA/mRNA and its interaction with chemotherapeutics. Domestic pigs were treated with three cycles of anthracycline drugs (DOX,

Indexed as

MicroRNAsAnimalsAntibiotics, AntineoplasticCardiotoxicityDoxorubicinRNA, CircularRNA, MessengerSus scrofaSwineAntibiotics, AntineoplasticDoxorubicinMicroRNAsRNA, CircularRNA, MessengercircRNAdoxorubicinmiRNAMyocetnetwork analysisporcine modeltarget prediction

Identifiers

PMID38136582
PMCPMC10741657
OpenAlexW4389049756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.